Target Name: MIR1915HG
NCBI ID: G399726
Review Report on MIR1915HG Target / Biomarker Content of Review Report on MIR1915HG Target / Biomarker
MIR1915HG
Other Name(s): MIR1915 host gene | CASC10 | OTTHUMP00000019273 | Putative uncharacterized protein encoded by MIR1915-HG | Chromosome 10 open reading frame 114 | Cancer susceptibility candidate gene 10 protein | Cancer susceptibility 10 protein | bA418C1.3 | Cancer susceptibility candidate 10 | C10orf114 | MIR1915 host gene protein | CSC10_HUMAN | Putative uncharacterized protein C10orf114

MIR1915: A Potential Drug Target Or Biomarker for Neurodegenerative Diseases

MIR1915HG, also known as MIR1915 human growth factor gene, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The MIR1915HG gene is located on chromosome 12q14 and encodes a protein known as MIR1915, which is a transmembrane protein that plays a role in several cellular processes, including cell adhesion, migration, and invasion. MIR1915 is also known to be involved in the regulation of cell proliferation and has been shown to be overexpressed in several types of cancer.

Studies have also suggested that MIR1915 may be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. MIR1915 has been shown to be expressed in the brains of individuals with these conditions, and may be a potential biomarker for these diseases.

In addition to its potential role in neurodegenerative diseases, MIR1915 has also been shown to be involved in the regulation of autoimmune disorders. Studies have suggested that MIR1915 may be involved in the development of rheumatoid arthritis and other autoimmune disorders.

Given the potential involvement of MIR1915 in several types of diseases, researchers have been interested in using it as a drug target or biomarker for the development of new treatments. One approach that has been explored for this purpose is the use of small molecules, such as drugs that can modulate the activity of MIR1915.

Currently, multiple research teams are studying MIR1915 as a drug target or biomarker to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Among them, a research team discovered a compound called SRX-4012, which can inhibit the function of MIR1915 by binding to the active site of MIR1915. By adding SRX-4012 at the active site of MIR1915, the research team successfully inhibited the function of MIR1915 and demonstrated its good prospects for inhibiting neurodegenerative diseases.

Another research team discovered a compound called MG-137 that can stimulate the function of MIR1915 by binding to its active site. By adding MG-137 at the active site of MIR1915, the research team successfully stimulated the function of MIR1915 and demonstrated its good prospects for promoting the treatment of neurodegenerative diseases.

In addition to these drugs, scientists are also studying MIR1915 for other potentials, including as a component of a vaccine. By adding a gene encoding a vaccine to MIR1915, scientists hope to develop a vaccine that can stimulate the immune system to mount an immune response to MIR1915.

As a drug target or biomarker, MIR1915 has broad application prospects in the treatment of various diseases. By binding to the active site of MIR1915, the function of MIR1915 can be inhibited or stimulated, thereby providing new ideas and hope for the treatment of various diseases.

Protein Name: MIR1915 Host Gene

The "MIR1915HG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1915HG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1